<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348216</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-101</org_study_id>
    <secondary_id>2015-005007-86</secondary_id>
    <nct_id>NCT02348216</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma</brief_title>
  <acronym>ZUMA-1</acronym>
  <official_title>A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2
      pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and
      Cohort 4, Cohort 5 and Cohort 6).

      The primary objectives of this study are:

        -  Phase 1 Study: Evaluate the safety of axicabtagene ciloleucel regimens

        -  Phase 2 Pivotal Study; Evaluate the efficacy of axicabtagene ciloleucel

        -  Phase 2 Safety Management Study: Assess the impact of prophylactic regimens or earlier
           interventions on the rate and severity of cytokine release syndrome (CRS) and neurologic
           toxicities
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">August 2035</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Study: Percentage of Participants Experiencing Adverse Events defined as Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 30 Days</time_frame>
    <description>Dose-limiting toxicity is defined as protocol-defined axicabtagene ciloleucel related events with onset within the first 30 days following axicabtagene ciloleucel infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Pivotal Study: Overall Response Rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma as determined by the study investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Safety Management Study: Incidence and Severity of CRS and Neurologic Toxicities</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Among participants who experience an objective response, DOR is defined as the date of their first objective response (which is subsequently confirmed) to disease progression per the revised IWG Response Criteria for Malignant Lymphoma or death regardless of cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Study: ORR</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the revised IWG Response Criteria for Malignant Lymphoma as determined as determined by the study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Study: ORR per Independent Radiological Review Committee (IRRC)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the IRRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per the revised IWG Response Criteria for Malignant Lymphoma or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>OS is defined as the time from axicabtagene ciloleucel infusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Clinically Significant Changes in Safety Lab Values</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Axicabtagene Ciloleucel Antibodies</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Levels of Anti-CD19 CAR T Cells in Blood)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Levels of Cytokines in Serum)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Safety Management Study: ORR</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the revised IWG Response Criteria for Malignant Lymphoma as determined by study investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Safety Management Study: Changes Over Time in the European Quality of Life Five Dimension Five Level Scale (EQ-5D)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The European Quality of Life Five Dimension Five Level Scale (EQ-5D) is a generic measure of health status that provides a simple descriptive profile and a single index value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 Safety Management Study: Changes Over Time in the Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Refractory Diffuse Large B Cell Lymphoma (DLBCL)</condition>
  <condition>Relapsed Diffuse Large B-Cell Lymphoma</condition>
  <condition>Transformed Follicular Lymphoma (TFL)</condition>
  <condition>Primary Mediastinal B-cell Lymphoma (PMBCL)</condition>
  <condition>High Grade B-cell Lymphoma (HGBCL)</condition>
  <arm_group>
    <arm_group_label>Axicabtagene Ciloleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.</description>
    <arm_group_label>Axicabtagene Ciloleucel</arm_group_label>
    <other_name>Yescarta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>Axicabtagene Ciloleucel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Administered according to package insert</description>
    <arm_group_label>Axicabtagene Ciloleucel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          1. Histologically confirmed:

               -  Diffuse Large B Cell Lymphoma (DLBCL)

               -  Primary Mediastinal Large B Cell Lymphoma (PMBCL)

               -  Transformation Follicular Lymphoma (TFL)

               -  High grade B-cell lymphoma (HGBCL)

          2. Chemotherapy-refractory disease, defined as one of more of the following:

               -  No response to last line of therapy i. Progressive disease (PD) as best response
                  to most recent therapy regimen ii. Stable disease (SD) as best response to most
                  recent therapy with duration no longer than 6 month from last dose of therapy OR

               -  Refractory post-autologous stem cell transplant (ASCT) i. Disease progression or
                  relapsed less than or equal to 12 months of ASCT (must have biopsy proven
                  recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT,
                  the individual must have had no response to or relapsed after the last line of
                  therapy

          3. Individuals must have received adequate prior therapy including at a minimum:

               -  anti-CD20 monoclonal antibody unless investigator determines that tumor is
                  CD20-negative and

               -  an anthracycline containing chemotherapy regimen

               -  for individual with transformed FL must have chemorefractory disease after
                  transformation to DLBCL.

          4. At least one measurable lesion per revised IWG Response Criteria

          5. Age 18 or older

          6. Eastern cooperative oncology group (ECOG) performance status of 0 or 1

          7. Absolute neutrophil count (ANC) ≥ 1000/uL

          8. Absolute lymphocyte count ≥ 100/uL

          9. Platelet count ≥ 75,000/uL

         10. Adequate renal, hepatic, pulmonary and cardiac function defined as:

               -  Creatinine clearance (as estimated by Cockcroft Gault) &gt; 60 mL/min

               -  Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &lt; 2.5 upper
                  limit of normal (ULN)

               -  Total bilirubin &lt; 1.5 mg/dl, except in individuals with Gilbert's syndrome

               -  Cardiac ejection fraction &gt;50%, no evidence of pericardial effusion as determined
                  by an echocardiogram (ECHO), and no clinically significant pleural effusion

               -  Baseline oxygen saturation &gt;92% on room air

         11. All individuals or legally appointed representatives/caregivers, must personally sign
             and date the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
             approved consent form before initiating any study specific procedures or activities.

         12. Relapsed or refractory large B-cell lymphoma including DLBCL, PMBCL, TFL, and HGBCL
             after two systemic lines of therapy

        Key Exclusion Criteria

          1. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g.
             cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3
             years

          2. History of allogeneic stem cell transplantation

          3. Prior CAR therapy or other genetically modified T cell therapy

          4. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
             requiring IV antimicrobials for management. Simple urinary tract infection (UTI) and
             uncomplicated bacterial pharyngitis are permitted if responding to active treatment

          5. History of HIV infection or acute or chronic active hepatitis B or C infection.
             Individuals with history of hepatitis infection must have cleared their infection as
             determined by standard serological and genetic testing per current Infectious Diseases
             Society of America (IDSA) guidelines

          6. Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases,
             or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma,
             cerebrospinal fluid malignant cells or brain metastases

          7. History or presence of CNS disorder such as seizure disorder, cerebrovascular
             ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS
             involvement

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon - Tennesee</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon-Methodist Healthcare System - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and transparency.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>18 months after study completion</ipd_time_frame>
    <ipd_access_criteria>A secured external environment with username, password, and RSA code.</ipd_access_criteria>
    <ipd_url>http://www.gilead.com/research/disclosure-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

